INZY Relative Valuation
INZY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INZY is overvalued; if below, it's undervalued.
Historical Valuation
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.11
P/B
Median3y
1.82
Median5y
1.93
-147.73
FCF Yield
Median3y
-45.00
Median5y
-34.06
Competitors Valuation Multiple
The average P/S ratio for INZY's competitors is 4.77, providing a benchmark for relative valuation. Inozyme Pharma Inc Corp (INZY) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
People Also Watch
MEG
Montrose Environmental Group Inc
14.260
USD
+0.49%
SHLS
Shoals Technologies Group Inc
3.330
USD
+1.22%
MLAB
Mesa Laboratories Inc
112.920
USD
-2.25%
PLYM
Plymouth Industrial REIT Inc
14.310
USD
+1.13%
CRON
Cronos Group Inc
1.770
USD
+2.91%
CPF
Central Pacific Financial Corp
24.920
USD
+0.32%
TCPC
BlackRock TCP Capital Corp
6.640
USD
-0.75%
CFFN
Capitol Federal Financial Inc
5.230
USD
+0.58%
CRML
Critical Metals Corp
2.250
USD
+4.65%
BFST
Business First Bancshares Inc
22.440
USD
+0.99%
FAQ
Is Inozyme Pharma Inc (INZY) currently overvalued or undervalued?
Inozyme Pharma Inc (INZY) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Inozyme Pharma Inc (INZY) is between to according to relative valuation methord.
What is Inozyme Pharma Inc (INZY) fair value?
How does INZY's valuation metrics compare to the industry average?
What is the current P/B ratio for Inozyme Pharma Inc (INZY) as of Apr 16 2025?
What is the current FCF Yield for Inozyme Pharma Inc (INZY) as of Apr 16 2025?
What is the current Forward P/E ratio for Inozyme Pharma Inc (INZY) as of Apr 16 2025?